更新于：2024-11-16

Clavulanic Acid

克拉维酸

更新于：2024-11-16

概要

概要

基本信息

药物类型

小分子化药

别名

(Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid、Clavulanate、Clavulanic acid (INN)

+ [10]

靶点

PSMA

作用机制

PSMA抑制剂(前列腺癌特异性膜抗原抑制剂)

治疗领域

泌尿生殖系统疾病其他疾病

在研适应症-

非在研适应症

重度抑郁症勃起功能障碍中度重度抑郁症

原研机构-

在研机构-

非在研机构

Rexahn Pharmaceuticals, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C8H9NO5

InChIKeyHZZVJAQRINQKSD-PBFISZAISA-N

CAS号58001-44-8

关联

项与克拉维酸相关的临床试验

CTIS2024-513753-75-00 / Not yet recruiting

- BLCL-AMC-03

开始日期2024-08-12

申办/合作机构-

CTIS2024-513752-15-00 / Not yet recruiting

- BLCL-AMC-02

开始日期2024-08-01

申办/合作机构-

CTIS2024-513751-32-00 / Not yet recruiting

- BLCL-AMC-01

开始日期2024-07-24

申办/合作机构-

100 项与克拉维酸相关的临床结果

登录后查看更多信息

100 项与克拉维酸相关的转化医学

登录后查看更多信息

100 项与克拉维酸相关的专利（医药）

登录后查看更多信息

8,985

项与克拉维酸相关的文献（医药）

2024-12-01·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Diverticulitis evaluation and management among United States emergency departments over an eight-year period

Article

作者: Gottlieb, Michael ; Moyer, Eric ; Bernard, Kyle ; Wusterbarth, Emily

INTRODUCTION:

Diverticulitis is a common reason for presentation to the Emergency Department (ED). However, as imaging options, risk stratification tools, and antibiotic options have expanded, there is a need for current data on the changes in incidence, computed tomography (CT) performance, antibiotic usage, and disposition over time.

METHODS:

This was a cross-sectional study of ED patients with a diagnosis of diverticulitis from 1/1/2016 to 12/31/2023. Using the Epic Cosmos database, all ED visits for acute diverticulitis were identified using ICD-10 codes. Outcomes included total ED presentations for diverticulitis, admission rates, CTs performed, outpatient antibiotic prescriptions, and antibiotics administered in the ED for admitted patients.

RESULTS:

There were 186,138,130 total ED encounters, with diverticulitis representing 927,326 (0.50 %). The rate of diverticulitis diagnosis increased from 0.40 % to 0.56 % over time. The admission rate declined over time from 33.6 % to 27.7 %, while the CT rate rose from 83.0 % to 92.6 %. Among those discharged, 90.4 % received an antibiotic, which remained consistent over time. Metronidazole (55.1 %) and ciprofloxacin (40.8 %) were the most commonly prescribed antibiotics, followed by amoxicillin-clavulanate (36.1 %). Among those admitted, most received either metronidazole (62.0 %), a fluoroquinolone (40.4 %), a third-generation cephalosporin (18.9 %), or a penicillin-based agent (38.1 %). Among both discharged and admitted patients, there was a marked shift to penicillin-based agents as the primary antibiotic regimen.

CONCLUSION:

Diverticulitis remains a common ED presentation, with a gradually rising incidence over time. Admission rates have decreased, while CT imaging has become more common. Most patients receive antibiotics, though the specific antibiotic has shifted in favor of penicillin-based agents. These findings can provide key benchmarking data and inform future initiatives to guide imaging and antibiotic use.

2024-12-01·One Health

Multi-drug resistant (MDR) and extended-spectrum β-lactamase (ESBL) producing Escherichia coli isolated from slaughtered pigs and slaughterhouse workers in Yaoundé, Cameroon

Article

作者: Noubom, Michel ; Dimani, Brice Davy ; Gonsu, Hortense ; Koudoum, Patrice Landry ; Founou, Luria Leslie ; Founou, Raspail Carrel ; Boum-II, Yap ; Matakone, Moise ; Fonkoua, Marie Christine ; Boum-Ii, Yap

Antimicrobial resistance (AMR) in the food chain remains a global public health concern for both humans and animals. This study aimed to determine the prevalence, resistance profiles, and clonal relatedness of multidrug-resistant (MDR) and extended-spectrum β-lactamases- producing Escherichia coli (ESBL-Ec) isolated from slaughtered pigs and slaughterhouse workers in Yaoundé, Cameroon. A cross-sectional study was conducted over four months, from February to May 2023 in two selected pig's slaughterhouse markets in Yaoundé. Rectal swabs were collected from 375 pigs at four time points and pooled per three according to gender, origin, and abattoirs leading to 125 pooled samples. Seven faecal samples from 60 contacted exposed workers were collected. Samples were cultured on CHROMagar™ ESBL medium, dark pink to reddish colonies were considered E. coli. Resistance genes including bla _CTX-M, bla _SHV and bla _TEM were detected using the polymerase chain reaction (PCR) while ERIC-PCR was used to assess the genetic relatedness between isolates. The prevalence of ESBL-Ec was elevated among exposed workers (71.4 %; n = 5/7) and pigs (70.4 %; n = 88/125). Overall, ESBL-Ec exhibited high resistance to cefuroxime (100 %, n = 105/105), cefotaxime (100 %, n = 105/105), amoxicillin-clavulanic acid (98.1 %, n = 103/105), cefixime (92.4 %, n = 97/105), tetracycline (86.7 %, n = 91/105) and sulfamethoxazole-trimethoprim (81.9 %, n = 86/105). However, these isolates showed good susceptibility to gentamicin (3.8 %, n = 4/105), chloramphenicol (8.6 %, n = 9/105), and fosfomycin (14.3 %, n = 15/105). All human isolates and 75.8 % (n = 75/99) of pig isolates were multi-drug resistant. The bla _CTX-M was the most prevalent resistance gene among exposed workers (100 %, n = 6/6) and pigs (80.8 %, n = 80/99) followed by bla _TEM (33.3 % each). High clonal relatedness of ESBL-Ec strains was observed among pig and human isolates across slaughterhouses. This study showed that the gastrointestinal tract of pigs might be an important reservoir of MDR and ESBL-Ec in Yaoundé, Cameroon and these resistant bacteria might be circulating between sources, especially humans. Heightening awareness on appropriate antibiotic use in humans and animals as well as implementing stringent biosecurity and food safety measures are imperative to prevent the emergence and spread of AMR in the country.

2024-12-01·MICROBIAL PATHOGENESIS

Whole genome sequencing reveals antibiotic resistance pattern and virulence factors in Klebsiella quasipneumoniae subsp. Similipneumoniae from Hospital wastewater in South-West, Nigeria

Article

作者: Akinola, Omowumi T ; Akinola, Omowumi T. ; Dahunsi, Samuel Olatunde

Klebsiella quasipneumoniae is a distinct species from K. pneumoniae, even though it is sometimes mistaken phenotypically for the latter in clinical situations. K. quasipneumoniae is a pathogen and this study aims at understanding the genomic antibiotic resistance and virulence characteristics of Klebsiella quasipneumoniae subsp. similipneumoniae (B105 strain) isolated from tertiary hospital wastewater and the potential risks associated with its environmental spread. The Illumina platform was used for whole-genome sequencing (WGS), the generated raw reads (de novo) was assembled using RAPT NCBI, while other standardized bioinformatics tools were utilized to validate and examine the landscape of the genome's antibiotic resistance and virulence factors. The K. quasipneumoniae subsp. similipneumoniae (B105 strain), belonged to sequence type 1422 and was resistant to ampicillin, amoxicillin-clavulanic acid, ceftazidime, cefepime, meropenem, tetracycline, but susceptible to gentamicin. The annotated genome acknowledged the presence of bla_OKP-B-2, ompK 36, fosA5, oqxAB, virulence genes responsible for capsule formation, lipopolysaccharide, iron uptake aerobactin (iutA), salmochelins (iroE, iroN), enterobactin siderophore, efllux pump (acrA, acrB) adherence, (mrkC, mrkD, and fimD) and two plasmids replicon IncFIB(K) and IncR. The study resonates the inadequacy of conventional microbiological identification methods to distinguish K. pneumoniae and K. quasipneumoniae and at the same time heightens the importance of using a genomic platform to extol the identity of K. quasipneumoniae subsp. similipneumoniae strain. Furthermore, the peculiarities of the acquired antimicrobial resistance and virulence genes, in this strain, are a potential risk to the environment.

项与克拉维酸相关的新闻（医药）

2024-11-06

·药渡

新药速递：FDA10月批准药物盘点

来源：药渡撰文：幻目编辑：维他命到目前为止，FDA在2024年已经批准了一些重磅新药，包括礼来用于治疗阿尔茨海默病的Kisunla和Madrigal制药公司治疗代谢功能障碍相关脂肪性肝炎的Rezdiffra，以及BMS的35年来第一种新型精神分裂症药物KarXT等。相关拓展：35年来首款！FDA批准BMS新型精神分裂症药物，5款新药紧随其后…… 10月又有一些新药获批，1家公司收到完整回复函（CRL）获批在望，以下汇总了10月FDA一些批准信息。 01 Scemblix 研发企业：诺华适应症：FDA批准了诺华Scemblix的适应症扩展，用于治疗成人费城染色体阳性慢性粒细胞白血病。 Scemblix是一种口服酪氨酸激酶抑制剂，通过阻断BCR-ABL1融合蛋白起作用，BCR-ABL1融合蛋白是某些白血病的已知标志物。该药物于三年前首次获批用于白血病，赢得了两个适应症。第一个是用于治疗费城染色体阳性的慢性期白血病，该药物获得了加速批准。第二种是完全批准相同的患者群体，并附加他们携带T315I突变。适应症扩展得到了III期ASC4FIRST研究数据的支持，该研究显示，68%的Scemblix 患者达到临床终点，而接受伊马替尼和尼洛替尼等标准治疗酪氨酸激酶抑制剂疗法的患者为49%。预计Scemblix的峰值销售额将超过30亿美元。 02 Jylamvo 研发企业：Shorla Oncology 适应症：小儿急性淋巴细胞白血病和多关节幼年特发性关节炎 Shorla Oncology获得Jylamvo的扩大批准，用于治疗急性淋巴细胞白血病（ALL）和多关节幼年特发性关节炎（pJIA）的儿科患者。据美国-爱尔兰专业制药公司称，Jylamvo是市场上唯一获准用于成人和儿童适应症的口服液体甲氨蝶呤。 Jylamvo于2022年11月首次获得批准，用于治疗患有急性淋巴细胞白血病、蕈样肉芽肿、复发或难治性非霍奇金淋巴瘤、类风湿性关节炎和严重银屑病的成人患者。 Shorla首席执行官Sharon Cunningham在一份声明中表示：“此次批准是基于Jylamvo在成年患者中成功使用之后，在解决肿瘤学和自身免疫性疾病中儿科护理未满足需求方面向前迈出的关键一步。” 03 Roxybond 研发企业：Protega Pharmaceuticals 适应症：剧烈疼痛专注于疼痛管理和新型抗滥用产品开发的Protega Pharmaceuticals公司宣布，FDA批准ROXYBOND™ 10mgTablet（盐酸羟可酮速释10mg片剂）用于治疗严重到需要使用阿片类止痛药且替代疗法不足的疼痛。 CDER已经批准了10种具有旨在阻止滥用性质的阿片类产品，但是除Roxybond之外的所有产品都是缓释/长效（ER/LA）制剂，Roxybond是FDA第一个获批的具有防滥用特性的速释（IR）阿片类药物。其采用SentryBond™防滥用技术配制而成，该药物采用多层包衣片剂的形式，通过物理及化学方法屏蔽以防滥用。实验数据显示，与其他速释阿片类止痛药物相比，Roxybond在抵抗切割、挤压、研磨或工具破坏方面有着显著提升。此外，在多种条件下，Roxybond药片可以抵抗家用或试验用溶剂，从而达到抗化学提取的效果。Roxybond含有的粘性材料还可以使药物难以通过针头进行注射，并且使溶液配制变得更加困难。由此，Roxybond可以很好地阻止经静脉内和鼻内（鼻吸）途径的滥用。除了FDA批准的10mg片剂外，ROXYBOND此前已获批准，目前已有5mg、15mg和30mg片剂。增加ROXYBOND 10mg可增强阿片类药物治疗的灵活性和精确性，旨在帮助医生和患者实现更有效、更安全的疼痛管理。 04 Orlynvah 研发企业：Iterum Therapeutics 适应症：尿路感染美国FDA批准Orlynvah用于治疗由指定微生物（大肠杆菌、肺炎克雷伯菌或奇异变形杆菌）引起的无并发症尿路感染（uUTIs）成年女性，这类患者没有或几乎没有可替代口服抗菌的治疗方案。根据新闻稿，Orlynvah是FDA批准的首个口服培南类抗生素，也是过去二十年中第二款获得FDA批准的uUTI治疗药物。 Orlynvah的批准得到了两项III期试验的支持。在关键的晚期REASSURE研究中，Iterum的药物在总体反应方面显示出不劣于Augmentin（阿莫西林/克拉维酸）的统计学非劣效性，而在关键的III期SURE1研究中，Orlynvah在喹诺酮类耐药感染患者中的表现优于环丙沙星。在两项研究中，治疗组之间的安全性相当。 05 Abrysvo 研发企业：辉瑞适应症：呼吸道合胞病毒在FDA扩大了辉瑞Abrysvo的标签后，患呼吸道合胞病毒（RSV）相关下呼吸道疾病风险较高的年轻人现在有了预防选择。据辉瑞公司称，Abrysvo是第一种可用于50岁以下成年人的RSV疫苗。 Abrysvo在III期MONeT试验中的“推断疗效”支持了标签扩展。根据辉瑞4月份披露的顶线数据，该试验达到了其主要疗效终点，在60岁及以上的年轻人中引发了非劣效免疫反应。 Abrysvo也是妊娠32至36周孕妇的唯一疫苗选择，旨在为从出生到6个月的婴儿提供保护。 06 Vyloy 研发企业：安斯泰来适应症：胃或胃食管交界处癌在FDA批准安斯泰来的Vyloy后，某些胃癌患者有了新的治疗选择。据安斯泰来称，获得批准后，Vyloy成为美国第一个针对胃或胃食管交界处癌的claudin18.2靶向疗法。 Vyloy被特别批准用于claudin18.2阳性HER2阴性肿瘤患者的一线治疗，联合含氟嘧啶和铂类化疗。该批准得到了III期SPOTLIGHT和GLOW研究数据的支持，这两项研究均达到了无进展生存期的主要终点和总生存期的关键次要终点。在这两项研究中，Vyloy的耐受性良好，最常见的副作用包括恶心、呕吐和食欲减弱。 07 Vyalev 研发企业：艾伯维适应症：帕金森病随着FDA批准艾伯维的Vyalev作为“第一个也是唯一一个基于左旋多巴的疗法皮下输注用于治疗运动波动”药物，这种新的非手术方案可在早、中、晚持续输送左旋多巴。对于晚期帕金森病（PD）患者来说，有了新的治疗选择。这一批准主要基于一项为期12周的关键性3期临床试验，该研究评估了Vyalev在晚期PD成人患者中持续皮下输注的疗效，并与口服即释型卡比多巴/左旋多巴进行了对比。此外，还有一项为期52周的开放标签研究，评估了Vyalev的长期安全性和有效性。关键性临床试验结果显示，接受Vyalev治疗的患者在运动能力波动改善方面表现出更佳效果，与口服药物相比，其运动症状控制较佳的时间增加，运动障碍症状回归的时间减少。在第12周时，Vyalev组运动症状控制较佳的时间增加2.72小时，活性对照组这一数值为0.97小时。 08 Lumryz 研发企业：Avadel Pharmaceuticals 适应症：与儿童发作性睡病相关的猝倒或白天过度嗜睡 Avadel Pharmaceuticals的Lumryz现已获准用于治疗7岁及以上患有白天过度嗜睡（EDS）或猝倒（突然肌肉无力）的儿科患者。 Lumryz是一种睡前服用的缓释羟丁酸钠制剂，最初于2023年5月1日获得FDA批准，用于治疗成年发作性睡病患者的猝倒或过度嗜睡症。Lumryz在成人中的批准基于3期临床试验REST-ON的积极结果。该研究表明，与安慰剂相比，在三项共同主要终点（即维持清醒测试、临床总体印象-改善评分以及每周平均猝倒发作次数）上，Lumryz的效果均具有高度统计学显著性（p<0.001）和临床意义。 LUMRYZ获得儿科使用批准对患有嗜睡症的儿童及其家庭来说是一项重要进展，因为它提供了一种无需半夜服药的一次性睡前治疗选择。FDA的决定得到了临床试验结果的支持，这些结果证明了该药物的有效性和安全性。随着其儿科批准，该药物还获得了孤儿药独占权，有效期至2031年10月16日，为Avadel在未来七年内提供了针对这一患者群体的市场独占权。 09 Hympavzi 研发企业：辉瑞适应症：血友病A和血友病B FDA批准辉瑞的Hympavzi作为美国第一个每周一次的血友病B皮下预防性注射用药。据辉瑞称，Hympavzi同时被授权用于治疗血友病A，也是第一种通过预装笔或注射器用于治疗两种疾病的方法。Hympavzi旨在用于常规预防，以降低血友病患者出血发作的频率或完全预防出血发作。 Hympavzi的批准得到了III期BASIS试验数据的支持，该试验招募了近190名重度A型血友病或中重度至重度B型血友病患者。在这项试验中，辉瑞药物治疗使得缺乏因子VIII或IX因子抑制剂的患者出血减少了92%，年出血率下降了35%。相关拓展：重磅首款！每周一次，辉瑞长效血友病疗法获FDA批准 10 dasiglucagon 研发企业：Zealand Pharma 适应症：先天性高胰岛素血症 Zealand Pharma收到了FDA关于达西格列酮（dasiglucagon）新药申请（NDA）第一部分的完整回复函（CRL），该药物用于预防和治疗7天及以上先天性高胰岛素血症（CHI）的儿科患者的低血糖症，最多服用3周。 CRL关注在第三方设施重新检查的时间安排，并没有提出关于dasiglucagon临床数据或安全性的问题。FDA要求从现有的CGM数据集中进行额外的分析，以支持在3周后使用dasiglucagon，Zealand Pharma预计将在2024年底之前提交相关数据。参考资料： https://www.biospace.com/biospace-fda-decision-tracker *声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！解决传统PROTACs、miRNA疗法关键挑战，miRiaTAC开启精准抗癌新征程直击“不死的癌症”红斑狼疮！数百条研发管线能否改写患者命运？药企裁员形势严峻依旧 | 十月汇总

上市批准加速审批临床3期申请上市医药出海

2024-10-28

·BioSpace

Iterum Wins FDA Approval For Oral UTI Antibiotic, Seeks ‘Strategic Transaction’ for Asset

iStock, hapabapa Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman said the company will renew its efforts to look for a potential partner to maximize value for its stakeholders. The FDA on Friday signed off on Iterum Therapeutics’ oral antibiotic sulopenem etzadroxil and probenecid, which will now be marketed as Orlynvah, for the treatment of uncomplicated urinary tract infections in adult women. Orlynvah, Iterum’s first FDA-approved product, is cleared for three designated microorganisms— Escherichia coli , Klebsiella pneumoniae and Proteus mirabilis —and is indicated for women with limited or no available alternative oral antibiotic options. Iterum CEO Corey Fishman in a statement called Orlynvah’s approval a “historic milestone” that “offers new hope for patients suffering from difficult-to-treat uUTIs (uncomplicated urinary tract infections).” Orlynvah is “the first oral penem approved in the U.S.,” Fishman said, noting it is “an important way to combat antimicrobial resistance to other approved oral agents and offers a potential solution to patients and physicians.” To bring Orlynvah to the market and boost its commercialization efforts, Iterum will “renew” its “efforts to achieve a strategic transaction involving Orlynvah with the goal of maximizing value for our stakeholders,” Fishman said. The FDA’s decision on Friday was backed by Iterum’s clinical data for Orlynvah, including two Phase III trials. In the pivotal late-stage REASSURE study, topline data which were released in January 2024 , the oral sulopenem showed statistical non-inferiority to Augmentin (amoxicillin/clavulanate) in terms of overall response. Orlynvah significantly outperformed Augmentin at overall treatment success. Safety outcomes were comparable between treatment groups. Iterum’s data package also included findings from the pivotal Phase III SURE 1 study, which in June 2020 showed that the oral sulopenem was better than ciprofloxacin in patients with quinolone-resistant infections. SURE 1 also found Orlynvah to be safe, with adverse events developing at a comparable frequency as in the ciprofloxacin-treated group. Iterum filed a New Drug Application to the FDA but failed to secure approval. In July 2021, the regulator handed the Dublin, Ireland-based biotech a Complete Response Letter, noting that while SURE 1 had established that oral sulopenem was superior than ciprofloxacin, Iterum would need to run an additional trial that uses a different comparator drug. Iterum filed its resubmission earlier this year, after which the FDA convened its Antimicrobial Drugs Advisory Committee. The panel was not asked to vote on the approvability of Orlynvah, but Fishman said in a statement after the meeting that the company was “encouraged” by the discussion, “which acknowledged oral sulopenem as an important treatment option for certain patients with uUTI.”

临床3期上市批准临床结果合格传染病产品

2024-10-25

·EndPoints

Iterum wins approval for new oral antibiotic for UTIs. Now it wants a partner

The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who have limited or no alternative oral options. Orlynvah, also known as oral sulopenem, will join a host of antibacterials already on the market for uUTIs. But because of growing antimicrobial resistance and unwanted side effects with some drugs, the company sees a chance to fill an unmet medical need. The drug will also be the first oral drug in a class of antibiotics known as “penems.” Iterum is now looking for a partner with “enough resources to be able to support an appropriate launch,” CEO Corey Fishman said in an interview with Endpoints News . If it can find a partner, Orlynvah could hit the market by the middle of next year. If not, Fishman said “we would consider doing it on our own.” “But we, of course, would have to raise substantial capital to do it,” he said. While the company had applied for broad use in adults with uUTIs, Fishman said the FDA’s label restrictions are “very consistent with how we’ve been thinking the whole time.” The drug is approved specifically for women with uUTIs caused by three microorganisms — Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis — who have limited options. Uncomplicated UTIs are one of the most frequently diagnosed bacterial infections in the US, generating millions of office visits per year, according to research from UCSF’s Department of Clinical Pharmacy. But last month, an FDA advisory committee that reviewed the company’s drug raised concerns about the risks of increasing antimicrobial resistance by opening the door to potential misuse. “We’re not for the otherwise healthy, younger adult woman who has a UTI,” Fishman told Endpoints News on Friday. “What we’ve always said is we are for that at-risk patient, that higher-risk patient, and I think the label supports that.” That jibes with the FDA’s concerns, which in briefing documents for the advisory committee said that an oral penem could result in “inappropriate and/or extensive use,” potentially leading to cross-resistance with carbapenems, a class of antibiotics commonly used for severe infections or in patients resistant to other antibiotics. “How would we feel as providers if we gave somebody courses of a penem antibiotic for a non-life threatening uncomplicated urinary tract infection, and then a month later, or two months later, or three months later, that patient gets admitted with sepsis due to a penem-resistant organism and dies from that infection?” asked Arjun Srinivasan, a deputy director in the CDC’s Division of Healthcare Quality Promotion, during the committee discussion in September. The FDA rejected the drug in 2021, citing a “lack of substantial evidence of effectiveness.” This time around, Iterum submitted new data showing it was superior to an oral amoxicillin/clavulanate regimen on overall clinical and microbiological response in patients susceptible to the comparator.

上市批准

100 项与克拉维酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07711	克拉维酸	J01	DB00766

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	临床2期	美国	Rexahn Pharmaceuticals, Inc.	2009-01-01
中度重度抑郁症	临床2期	美国	Rexahn Pharmaceuticals, Inc.	2009-01-01
勃起功能障碍	临床2期	美国	Rexahn Pharmaceuticals, Inc.	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAAAI2010	N/A	超敏反应	-	Amoxicillin-Clavulanic Acid	憲構蓋遞範艱鬱襯艱構(構餘觸顧顧衊構鹹齋鏇) = 衊簾鏇夢夢簾襯窪簾艱構鏇簾鹹鹹範願範遞積 (繭積鬱製願醖鏇壓齋壓 )	-	2010-02-01
				Benzylpenicillin	憲構蓋遞範艱鬱襯艱構(構餘觸顧顧衊構鹹齋鏇) = 鹽鹽蓋蓋範觸襯醖繭窪構鏇簾鹹鹹範願範遞積 (繭積鬱製願醖鏇壓齋壓 )